Brokerages set USD 45.17 target for Indivior stock

Published on 10/20/2026 at 18:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Indivior booked USD 343.00 million revenue in the second quarter of 2026. Indivior stock costs EUR 30.50 on October 20, 2026 at 6:37 p.m. CEST.

Analyst target and reporting date

Seven brokerages put the average Indivior target at USD 45.17 on October 15, 2026.
Indivior reported USD 343.00 million in second-quarter 2026 revenue.
Indivior stock costs EUR 30.50 at Lang & Schwarz on October 20, 2026 at 6:37 p.m. CEST.

Moderne Pharma-Produktionsanlage mit Glasfassade und Industrieanlagen im Tageslicht — Indivior PLC mit ISIN GB00BYZ0C031 betreibt moderne Pharma-Produktionsanlage für innovative Suchtmedizin-Präparate weltweit an Patienten, Illustration mit AI erstellt.

According to MarketBeat on October 15, 2026, seven research firms put Indivior's average 12-month price target at USD 45.17. Indivior reported USD 343.00 million in revenue for the second quarter of 2026. At Lang & Schwarz, the stock was trading at EUR 30.50 on October 20, 2026 at 6:37 p.m. CEST.

Target leaves a 31.42 percent gap

The consensus target stands 31.42 percent above the Nasdaq price of USD 34.37 on October 20, 2026. That calculation uses the USD target and the same-day USD quotation, keeping the analyst comparison separate from the euro quote used for German investors.

MarketBeat also listed five Buy ratings, one Strong Buy rating and one Hold rating among the seven firms. Barclays had previously lowered its target from USD 46.00 to USD 43.00 on August 5, 2026, while Craig Hallum maintained a Buy rating and a USD 53.00 target on August 4, 2026, according to MarketBeat.

Price sits inside the yearly range

Indivior traded at USD 34.37 on Nasdaq at 12:45 p.m. EDT on October 20, 2026, with a market capitalization of USD 4.3 billion. Its 52-week range was USD 23.99 to USD 42.81 on the same market-data date, placing the stock below its yearly high while keeping it above the low.

Indivior develops medicines for substance-use disorders and serious mental health conditions. Its second-quarter revenue of USD 343.00 million gives the next results release a clear operating benchmark.

Results are scheduled for October 29

MarketScreener lists October 29, 2026 as the date for Indivior's third-quarter 2026 earnings release. The next report will show whether the USD 343.00 million second-quarter revenue level carried into the following period.

Investor view

The analyst range remains wide, from USD 43.00 for the reduced Barclays target to USD 53.00 from Craig Hallum, while the seven-firm average is USD 45.17. For investors, the October 29 results date is the next scheduled checkpoint for the revenue trend and the valuation discussion.

Indivior was trading at EUR 30.50 at Lang & Schwarz on October 20, 2026 at 6:37 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Indivior stock.